Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q1 FY27 results · Apr–Jun 2026
Ajanta Pharma reported revenue from operations of ₹1,625.96 crore (up 24.8% from Q1 FY26) and net profit of ₹334.22 crore (up 30.9% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a consolidated basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,625.96 | 1,302.65 | +24.8% | 1,421.64 | +14.4% |
| Other income | 70.90 | 26.33 | +169.3% | 61.43 | +15.4% |
| Total income | 1,696.86 | 1,328.98 | +27.7% | 1,483.07 | +14.4% |
| Profit before tax | 446.80 | 331.13 | +34.9% | 347.11 | +28.7% |
| Net profit for the period | 334.22 | 255.34 | +30.9% | 266.70 | +25.3% |
| Attributable to shareholders of the company | 329.96 | 255.34 | +29.2% | 266.70 | +23.7% |
| EPS, basic (₹) | 26.75 | 20.44 | +30.9% | 21.35 | +25.3% |
| Net margin (%) | 20.6 | 19.6 | 18.8 |
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,488.67 | 1,208.56 | +23.2% | 1,210.53 | +23.0% |
| Other income | 70.82 | 40.63 | +74.3% | 62.98 | +12.4% |
| Total income | 1,559.49 | 1,249.19 | +24.8% | 1,273.51 | +22.5% |
| Profit before tax | 423.45 | 328.99 | +28.7% | 257.61 | +64.4% |
| Net profit for the period | 315.47 | 254.97 | +23.7% | 197.28 | +59.9% |
| EPS, basic (₹) | 25.25 | 20.41 | +23.7% | 15.79 | +59.9% |
| Net margin (%) | 21.2 | 21.1 | 16.3 |
Consolidated
- Filed with BSE
- 30 Jul 2026, 15:41 IST
- Board meeting
- 30 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jul 2026, 15:41 IST
- Board meeting
- 30 Jul 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE